论文部分内容阅读
目的观察金属硫蛋白制剂对肿瘤患者放化疗的疗效及不良反应。方法将符合入组条件的113例患者随机分为观察组(57例)和对照组(56例),观察组在常规放化疗前3天开始口服外源性锌金属硫蛋白制剂,每天1.8mg,配合常规放疗和(或)化疗直至治疗结束;对照组常规放疗和(或)化疗。两组患者在治疗前、治疗中和治疗后分别测定血常规、肝肾功能、心肌酶、CD3+和CD4+T淋巴细胞等以及治疗结束1个月后的缓解率(CR+PR)和3年生存率。结果两组患者的CD3+和CD4+T淋巴细胞在放化疗过程中呈下降趋势,但观察组治疗后的CD3+和CD4+T淋巴细胞高于对照组,差异有统计学意义(P﹤0.05);两组患者的外周血白细胞计数、血红蛋白量、血小板计数、心肌酶(CK)、肝功能(ALT和AST)、肾功能(BUN和Scr)在治疗前、治疗中及治疗后比较,差异无统计学意义(P>0.05);两组患者治疗后的客观缓解率和3年生存率比较,差异无统计学意义(P>0.05)。结论外源性锌金属硫蛋白对放化疗引起的T细胞损伤有保护作用,而对血常规、肝肾功能、心肌酶、放化疗的疗效及治疗后的3年生存率无明显影响。
Objective To observe the curative effect and adverse reactions of metallothionein preparations on radiotherapy and chemotherapy in cancer patients. Methods A total of 113 patients eligible for inclusion were randomly divided into observation group (57 cases) and control group (56 cases). The observation group received oral zinc metallothionein preparation 3 days before routine radiotherapy and chemotherapy, , With conventional radiotherapy and / or chemotherapy until the end of treatment; control group conventional radiotherapy and / or chemotherapy. Two groups of patients before treatment, after treatment and after treatment were measured blood, liver and kidney function, myocardial enzymes, CD3 and CD4 T lymphocytes and the end of treatment after 1 months of remission rate (CR + PR) and 3 years Survival rate. Results The CD3 + and CD4 + T lymphocytes in both groups showed a decreasing trend during radiotherapy and chemotherapy, but the levels of CD3 + and CD4 + T lymphocytes in the observation group were significantly higher than those in the control group (P <0.05). There were no differences in the levels of peripheral blood leukocyte count, hemoglobin, platelet count, CK, ALT, AST, BUN and Scr before treatment, after treatment and after treatment (P> 0.05). There was no significant difference between the two groups in objective response rate and 3-year survival rate after treatment (P> 0.05). Conclusion Exogenous zinc metallothionein has a protective effect on T cell injury induced by radiotherapy and chemotherapy. However, it has no significant effect on blood routine, liver and kidney function, myocardial enzyme, radiochemotherapy and 3-year survival rate after treatment.